University of Texas/Texas AM Investment Management Co (UTIMCO) Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$474K |
| 2 |
Carriage Services
CSV
|
+$106K |
| 3 |
Apple
AAPL
|
+$55K |
| 4 |
PX
Praxair Inc
PX
|
+$43.6K |
| 5 |
iShares Russell Mid-Cap Growth ETF
IWP
|
+$20K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alaunos Therapeutics
TCRT
|
+$105M |
| 2 |
Precigen
PGEN
|
+$66.8M |
| 3 |
SAGE
Sage Therapeutics
SAGE
|
+$551K |
| 4 |
Vanguard S&P 500 ETF
VOO
|
+$63.1K |
| 5 |
Vanguard FTSE Emerging Markets ETF
VWO
|
+$59.8K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 55.02% |
| 2 | Energy | 9.94% |
| 3 | Technology | 3.74% |
| 4 | Materials | 1.29% |
| 5 | Consumer Discretionary | 0.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
ExxonMobil
XOM
$652B
| $3K | 0.01% |
34
-76
| -69% | -$6.08K |
|
|
ESRX
27
DELISTED
Express Scripts Holding Company
ESRX
| $3K | 0.01% |
+38
| New | +$3.25K |
|
28
Zoetis
ZTS
$30.6B
| $2K | ﹤0.01% |
+32
| New | +$1.45K |
|
|
CST
29
DELISTED
CST Brands, Inc.
CST
| $2K | ﹤0.01% |
+55
| New | +$2.01K |
|
30
Alphabet (Google) Class C
GOOG
$4.21T
| $1K | ﹤0.01% |
+20
| New | +$718 |
|
31
IBM
IBM
$224B
| – | – |
-126
| Closed | -$17K |
|
32
Kinder Morgan
KMI
$70.7B
| – | – |
-1,912
| Closed | -$53K |
|
33
Pfizer
PFE
$151B
| – | – |
-105
| Closed | -$3K |
|
|
34
Precigen
PGEN
$2.48B
| – | – |
-2,118,986
| Closed | -$66.8M |
|
35
Raymond James Financial
RJF
$35B
| – | – |
-32
| Closed | -$1K |
|
|
SAGE
36
DELISTED
Sage Therapeutics
SAGE
| – | – |
-13,018
| Closed | -$551K |
|
Similar funds
University of Texas/Texas AM Investment Management Co (UTIMCO)'s Q4 2015 Portfolio in Review
As of Q4 2015, University of Texas/Texas AM Investment Management Co (UTIMCO) held 36 positions worth $48.6M, down 76% from $203M the previous quarter. Its ten largest holdings account for 96% of the portfolio.
University of Texas/Texas AM Investment Management Co (UTIMCO) withdrew a net $172M in Q4 2015, closing 6 positions and reducing 8 holdings. Its most notable exit was Precigen, an estimated $66.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 89% a quarter earlier, followed by Energy and Technology.
Against the trend, University of Texas/Texas AM Investment Management Co (UTIMCO) opened a new position in Bristol-Myers Squibb worth $494K.
- University of Texas/Texas AM Investment Management Co (UTIMCO)'s largest Q4 2015 buy was Bristol-Myers Squibb: 7,180 shares worth $494K.
- University of Texas/Texas AM Investment Management Co (UTIMCO)'s biggest Q4 2015 reduction was Alaunos Therapeutics, cutting an estimated $105M.
- University of Texas/Texas AM Investment Management Co (UTIMCO) fully exited Precigen in Q4 2015, selling an estimated $66.8M.
- University of Texas/Texas AM Investment Management Co (UTIMCO)'s ten largest holdings make up 96% of its $48.6M portfolio in Q4 2015.
- University of Texas/Texas AM Investment Management Co (UTIMCO) opened 14 new positions and closed 6 in Q4 2015.
- University of Texas/Texas AM Investment Management Co (UTIMCO)'s portfolio value fell 76% quarter-over-quarter to $48.6M.
Based on University of Texas/Texas AM Investment Management Co (UTIMCO)'s 13F filing for Q4 2015, filed 5 Feb 2016.